WO2007112047A3 - Formulations contenant des immunotoxines ciblées sur l'antigène de cellules mésothéliennes - Google Patents

Formulations contenant des immunotoxines ciblées sur l'antigène de cellules mésothéliennes Download PDF

Info

Publication number
WO2007112047A3
WO2007112047A3 PCT/US2007/007342 US2007007342W WO2007112047A3 WO 2007112047 A3 WO2007112047 A3 WO 2007112047A3 US 2007007342 W US2007007342 W US 2007007342W WO 2007112047 A3 WO2007112047 A3 WO 2007112047A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor cell
formulations containing
cell antigen
immunotoxins targeted
containing immunotoxins
Prior art date
Application number
PCT/US2007/007342
Other languages
English (en)
Other versions
WO2007112047A2 (fr
Inventor
Stephen Youngster
Qing-Hong Dai
Diane Change
Original Assignee
Enzon Pharmaceuticals Inc
Stephen Youngster
Qing-Hong Dai
Diane Change
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc, Stephen Youngster, Qing-Hong Dai, Diane Change filed Critical Enzon Pharmaceuticals Inc
Publication of WO2007112047A2 publication Critical patent/WO2007112047A2/fr
Publication of WO2007112047A3 publication Critical patent/WO2007112047A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des formulations liquides et lyophilisées d'immunotoxine SS1P présentant une grande stabilité et une durée de conservation prolongée. L'immunotoxine qu'elles contiennent possède des quantités très élevées d'activité résiduelle même après de longues périodes de stockage à 4 °C et même à la température ambiante.
PCT/US2007/007342 2006-03-24 2007-03-22 Formulations contenant des immunotoxines ciblées sur l'antigène de cellules mésothéliennes WO2007112047A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78558906P 2006-03-24 2006-03-24
US60/785,589 2006-03-24

Publications (2)

Publication Number Publication Date
WO2007112047A2 WO2007112047A2 (fr) 2007-10-04
WO2007112047A3 true WO2007112047A3 (fr) 2008-07-17

Family

ID=38541709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007342 WO2007112047A2 (fr) 2006-03-24 2007-03-22 Formulations contenant des immunotoxines ciblées sur l'antigène de cellules mésothéliennes

Country Status (1)

Country Link
WO (1) WO2007112047A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
US11311628B2 (en) 2016-10-17 2022-04-26 Duke University Production of immunotoxin D2C7—(scdsFv)—PE38KDEL

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917021A (en) * 1995-04-07 1999-06-29 Enzon, Inc. Stabilized monomeric protein compositions
WO2003009817A2 (fr) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Formulation pharmaceutique lyophilisee stable d'anticorps igg
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917021A (en) * 1995-04-07 1999-06-29 Enzon, Inc. Stabilized monomeric protein compositions
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
WO2003009817A2 (fr) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Formulation pharmaceutique lyophilisee stable d'anticorps igg

Also Published As

Publication number Publication date
WO2007112047A2 (fr) 2007-10-04

Similar Documents

Publication Publication Date Title
WO2007044084A3 (fr) Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation
WO2007095594A3 (fr) Méthodes et compositions pour renforcer l'implantation de cellules souches hématopoïétiques
IL177326A0 (en) Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors
EP1859812A4 (fr) Polymère chargeable de polycations et utilisation comme vecteur d'acides nucléiques
ZA200800818B (en) Plant support formulation, vehicle for the delivery and translocation of phytologically beneficial substances and compositions containing same
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
WO2011072246A3 (fr) Modification de l'adn induite par l'effecteur tal
WO2007003382A8 (fr) Milieu de conservation pour cellules
EP1906838A4 (fr) Modulation d'interaction de pathogenes microbiens-cellules hotes
WO2002028999A3 (fr) Profils d'expression genique dans les cellules granulocytaires
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
WO2010120368A3 (fr) Stabilisation de compositions radiopharmaceutiques à l'aide d'acide ascorbique
BRPI0812865A2 (pt) Derivados de 6-anilinopurina substituída como inibidores de citoquinina oxidase/desidrogenase e preparações contendo esses derivados.
WO2007097993A3 (fr) Milieu conditionné par des cellules souches embryonnaires humaines ou autres cellules progénitrices et son utilisation
EP1942153A4 (fr) Composition pouvant etre durcie amelioree dans sa capacite de durcissement et dans sa stabilite au stockage
AU304857S (en) Media player
HK1142536A1 (en) Gel useful for the delivery of cosmetic active ingredients
WO2007038627A3 (fr) Compositions antimicrobiennes stabilisees et methodes de preparation associees
GB0818613D0 (en) In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
ZA200902118B (en) Improvement of the biological action of agrochemical compositions when applied to the cultivation substrate, suitable formulations and use thereof
FR2920774B1 (fr) Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant
WO2005094364A3 (fr) Proteine d'anticorps iga utilisee en tant que medicament cytotoxique
WO2007112047A3 (fr) Formulations contenant des immunotoxines ciblées sur l'antigène de cellules mésothéliennes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07753926

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07753926

Country of ref document: EP

Kind code of ref document: A2